Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

Jason D. Lickliter, Kenneth Lawrence, John O’Donnell, Robin Isaacs

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a B-Lactamase Inhibitor, in Healthy Subjects

Antimicrobial Agents and Chemotherapy, July 2020 Volume 64 Issue 7 e00071-20

Harald Seifert, Carina Muller, Danuta Stefanik, Paul G. Higgins, Alita Miller and Michael Kresken

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy, June 2020

Olexiy Sagan, Ruslan Yakubsevitch, Krassimir Yanev, Roman Fomkin, Emily Stone, Daniel Hines, John O’Donnell, Alita Miller, Robin Isaacs, Subasree Srinivasan

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

American Society for Microbiology, Antimicrob Agents Chemotherapy March 2020 Volume 64 Issue 3 e01506-19

McLeod SM, Moussa SH, Hackel MA, Miller AA

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Antimicrobial Agents and Chemotherapy posted online January 27, 2020

John O’Donnell, Richard A. Preston, Grigor Mamikonyan, Emily Stone, Robin Isaacs

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

American Society for Microbiology, Antimicrob. Agents Chemother. August 2019 63:e00794-19; Accepted manuscript posted online 15 July 2019, doi:10.1128/AAC.00794-19 OPEN ACCESS

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor, Zoliflodacin

Journal of Clinical Microbiology

Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John O’Donnell, Joseph D. Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather,k,l Michael R. Jacobs, Krisztina M. Papp-Wallace, Focco van den Akker, Robert A. Bonomo

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

mBio. 2019 10(2): e00159-19

Iyer R, Moussa S, Tommasi R, Miller A.

Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux

National Center for Biotechnology Information

Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D., Arlene C. Seña, M.D., M.P.H., Jill Long, M.D., M.P.H., Michael R. Wierzbicki, Ph.D., Hannah Kwak, M.H.S., Shacondra M. Johnson, B.S.P.H., Kenneth Lawrence, Pharm.D., and John Mueller, Ph.D.

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

New England Journal of Medicine